Trial Profile
A Prospective, Multi-center, Phase 1b/2a Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Association With Teplizumab in Patients With Clinical Recent-onset Type 1 Diabetes Mellitus (T1D)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Oct 2023
Price :
$35
*
At a glance
- Drugs AG-019 (Primary) ; Teplizumab (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors ActoBio Therapeutics; Precigen Inc
- 02 Oct 2023 Results (n=42) assessing safety of AG019 as monotherapy and in combination with teplizumab in recent-onset type 1 diabetes patients, published in the Diabetologia..
- 09 Nov 2021 Status changed from active, no longer recruiting to completed.
- 09 Aug 2021 According to a Precigen Inc media release, additional data from trial will be presented at the European Association for the Study of Diabetes (EASD) 57th Annual Meeting and will be presented by Chantal Mathieu.